PLGA implants for controlled drug release: Impact of the diameter

Area of Science:

• Biomaterials Science
• Pharmaceutical Technology
• Drug Delivery Systems

Background:

• Poly(lactic-co-glycolic acid) (PLGA) is a widely used biodegradable polymer for drug delivery implants.
• Controlling drug release kinetics from PLGA implants is crucial for therapeutic efficacy.
• Implant geometry, specifically diameter, is a potential factor influencing drug release.

Purpose of the Study:

• To investigate the impact of poly(lactic-co-glycolic acid) (PLGA) implant diameter on drug release performance.
• To understand how varying implant dimensions affect the control of ibuprofen release from PLGA systems.

Main Methods:

• Preparation of ibuprofen-loaded PLGA implants using hot melt extrusion.
• Drug release studies conducted in phosphate buffer and agarose gel environments.
• Characterization of implant changes including mass, volume, molecular weight, and morphology (SEM).
• Analysis of drug and polymer physical states (DSC) and release medium pH.

Main Results:

• Drug release rates (absolute and relative) decreased as implant diameter increased from 0.7 mm to 2.8 mm.
• Bi-phasic drug release was observed, characterized by an initial zero-order phase followed by a rapid release phase.
• Increasing implant diameter delayed the onset of the final rapid drug release phase.

Conclusions:

• Implant diameter is a critical parameter for modulating drug release from PLGA systems.
• Larger diameters increase diffusion path lengths, slowing down drug release.
• Enhanced mechanical stability of thicker implants may also contribute to delayed drug release by resisting swelling.